{"id":"https://openalex.org/W4404226397","doi":"https://doi.org/10.1177/1759720x241288071","title":"Association of achieving clinical disease control criteria and patient-reported outcomes in bimekizumab-treated patients with active psoriatic arthritis: results from two phase III studies","display_name":"Association of achieving clinical disease control criteria and patient-reported outcomes in bimekizumab-treated patients with active psoriatic arthritis: results from two phase III studies","publication_year":2024,"publication_date":"2024-01-01","ids":{"openalex":"https://openalex.org/W4404226397","doi":"https://doi.org/10.1177/1759720x241288071","pmid":"https://pubmed.ncbi.nlm.nih.gov/39534481","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/11555751"},"language":"en","primary_location":{"id":"doi:10.1177/1759720x241288071","doi":"https://doi.org/10.1177/1759720x241288071","is_oa":true,"landing_page_url":"https://doi.org/10.1177/1759720x241288071","pdf_url":null,"source":{"id":"https://openalex.org/S138391592","display_name":"Therapeutic Advances in Musculoskeletal Disease","issn_l":"1759-720X","issn":["1759-720X","1759-7218"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","norway-1","oarl","poland-140","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Therapeutic Advances in Musculoskeletal Disease","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1177/1759720x241288071","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5023940584","display_name":"Lars Erik Kristensen","orcid":"https://orcid.org/0000-0002-0686-7102","observed_orcids":["https://orcid.org/0000-0002-0686-7102","https://orcid.org/0000-0003-1159-3721"]},"institutions":[{"id":"https://openalex.org/I2801941904","display_name":"Bispebjerg Hospital","ror":"https://ror.org/00td68a17","country_code":"DK","type":"healthcare","lineage":["https://openalex.org/I2801941904","https://openalex.org/I2802567020"]},{"id":"https://openalex.org/I2802567020","display_name":"Copenhagen University Hospital","ror":"https://ror.org/05bpbnx46","country_code":"DK","type":"healthcare","lineage":["https://openalex.org/I2802567020"]}],"countries":["DK"],"is_corresponding":true,"raw_author_name":"Lars Erik Kristensen","raw_affiliation_strings":["The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Nordre Fasanvej 57, Road 8, Entrance 19, DK-2000 Frederiksberg, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Nordre Fasanvej 57, Road 8, Entrance 19, DK-2000 Frederiksberg, Denmark","institution_ids":["https://openalex.org/I2801941904","https://openalex.org/I2802567020"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010193939","display_name":"William L. Tillett","orcid":"https://orcid.org/0000-0001-7531-4125","observed_orcids":["https://orcid.org/0000-0001-7531-4125"]},"institutions":[{"id":"https://openalex.org/I1291344717","display_name":"Royal National Hospital for Rheumatic Diseases","ror":"https://ror.org/05va5gy74","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1291344717","https://openalex.org/I4210161895"]},{"id":"https://openalex.org/I51601045","display_name":"University of Bath","ror":"https://ror.org/002h8g185","country_code":"GB","type":"education","lineage":["https://openalex.org/I51601045"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"William Tillett","raw_affiliation_strings":["Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, UK","Royal National Hospital of Rheumatic Diseases, Bath, UK"],"raw_orcid":"https://orcid.org/0000-0001-7531-4125","affiliations":[{"raw_affiliation_string":"Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, UK","institution_ids":["https://openalex.org/I51601045"]},{"raw_affiliation_string":"Royal National Hospital of Rheumatic Diseases, Bath, UK","institution_ids":["https://openalex.org/I1291344717"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011826741","display_name":"Peter T. Nash","orcid":"https://orcid.org/0000-0002-2571-788X","observed_orcids":["https://orcid.org/0000-0002-2571-788X"]},"institutions":[{"id":"https://openalex.org/I11701301","display_name":"Griffith University","ror":"https://ror.org/02sc3r913","country_code":"AU","type":"education","lineage":["https://openalex.org/I11701301"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Peter Nash","raw_affiliation_strings":["School of Medicine, Griffith University, Brisbane, QLD, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"School of Medicine, Griffith University, Brisbane, QLD, Australia","institution_ids":["https://openalex.org/I11701301"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085522760","display_name":"Laura C. Coates","orcid":"https://orcid.org/0000-0002-4756-663X","observed_orcids":["https://orcid.org/0000-0002-4756-663X"]},"institutions":[{"id":"https://openalex.org/I40120149","display_name":"University of Oxford","ror":"https://ror.org/052gg0110","country_code":"GB","type":"education","lineage":["https://openalex.org/I40120149"]},{"id":"https://openalex.org/I4210147381","display_name":"Oxford University Hospitals NHS Trust","ror":"https://ror.org/03h2bh287","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I4210147381"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Laura C. Coates","raw_affiliation_strings":["Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Diseases, University of Oxford and Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford, UK"],"raw_orcid":"https://orcid.org/0000-0002-4756-663X","affiliations":[{"raw_affiliation_string":"Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Diseases, University of Oxford and Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford, UK","institution_ids":["https://openalex.org/I40120149","https://openalex.org/I4210147381"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081778211","display_name":"Philip J. Mease","orcid":"https://orcid.org/0000-0002-6620-0457","observed_orcids":["https://orcid.org/0000-0002-6620-0457"]},"institutions":[{"id":"https://openalex.org/I201448701","display_name":"University of Washington","ror":"https://ror.org/00cvxb145","country_code":"US","type":"education","lineage":["https://openalex.org/I201448701"]},{"id":"https://openalex.org/I4210093417","display_name":"Swedish Medical Center","ror":"https://ror.org/004jktf35","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210093417","https://openalex.org/I94396219"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Philip J. Mease","raw_affiliation_strings":["Swedish Medical Center and Providence St. Joseph Health and University of Washington, Seattle, WA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Swedish Medical Center and Providence St. Joseph Health and University of Washington, Seattle, WA, USA","institution_ids":["https://openalex.org/I201448701","https://openalex.org/I4210093417"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014427334","display_name":"Alexis Ogdie","orcid":"https://orcid.org/0000-0002-4639-0775","observed_orcids":["https://orcid.org/0000-0002-4639-0775"]},"institutions":[{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alexis Ogdie","raw_affiliation_strings":["Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA","institution_ids":["https://openalex.org/I79576946"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087192032","display_name":"Paolo Gisondi","orcid":"https://orcid.org/0000-0002-1777-9001","observed_orcids":["https://orcid.org/0000-0002-1777-9001"]},"institutions":[{"id":"https://openalex.org/I119439378","display_name":"University of Verona","ror":"https://ror.org/039bp8j42","country_code":"IT","type":"education","lineage":["https://openalex.org/I119439378"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Paolo Gisondi","raw_affiliation_strings":["Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy","institution_ids":["https://openalex.org/I119439378"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011476143","display_name":"Barbara S. Ink","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210134054","display_name":"UCB Pharma (United Kingdom)","ror":"https://ror.org/03428qp74","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210134054","https://openalex.org/I85722119"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Barbara Ink","raw_affiliation_strings":["UCB, Slough, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCB, Slough, UK","institution_ids":["https://openalex.org/I4210134054"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001063897","display_name":"Adam R. Prickett","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210134054","display_name":"UCB Pharma (United Kingdom)","ror":"https://ror.org/03428qp74","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210134054","https://openalex.org/I85722119"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Adam R. Prickett","raw_affiliation_strings":["UCB, Slough, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCB, Slough, UK","institution_ids":["https://openalex.org/I4210134054"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042414114","display_name":"Rajan Bajracharya","orcid":"https://orcid.org/0009-0000-7857-8783","observed_orcids":["https://orcid.org/0009-0000-7857-8783"]},"institutions":[{"id":"https://openalex.org/I4210134054","display_name":"UCB Pharma (United Kingdom)","ror":"https://ror.org/03428qp74","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210134054","https://openalex.org/I85722119"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Rajan Bajracharya","raw_affiliation_strings":["UCB, Slough, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCB, Slough, UK","institution_ids":["https://openalex.org/I4210134054"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063754167","display_name":"V. Taieb","orcid":"https://orcid.org/0000-0003-0655-8630","observed_orcids":["https://orcid.org/0000-0003-0655-8630"]},"institutions":[{"id":"https://openalex.org/I4210103390","display_name":"UCB Pharma (France)","ror":"https://ror.org/01n6t9x28","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210103390","https://openalex.org/I85722119"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Vanessa Taieb","raw_affiliation_strings":["UCB, Colombes, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCB, Colombes, France","institution_ids":["https://openalex.org/I4210103390"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087345814","display_name":"Nikos Lyris","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210134054","display_name":"UCB Pharma (United Kingdom)","ror":"https://ror.org/03428qp74","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210134054","https://openalex.org/I85722119"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Nikos Lyris","raw_affiliation_strings":["UCB, Slough, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCB, Slough, UK","institution_ids":["https://openalex.org/I4210134054"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060762878","display_name":"J\u00e9r\u00e9my Lambert","orcid":"https://orcid.org/0000-0002-7164-1492","observed_orcids":["https://orcid.org/0000-0002-7164-1492"]},"institutions":[{"id":"https://openalex.org/I4210103390","display_name":"UCB Pharma (France)","ror":"https://ror.org/01n6t9x28","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210103390","https://openalex.org/I85722119"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"J\u00e9r\u00e9my Lambert","raw_affiliation_strings":["UCB, Colombes, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCB, Colombes, France","institution_ids":["https://openalex.org/I4210103390"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5033565189","display_name":"Jessica A. Walsh","orcid":"https://orcid.org/0000-0002-4563-0845","observed_orcids":["https://orcid.org/0000-0002-4563-0845"]},"institutions":[{"id":"https://openalex.org/I223532165","display_name":"University of Utah","ror":"https://ror.org/03r0ha626","country_code":"US","type":"education","lineage":["https://openalex.org/I223532165"]},{"id":"https://openalex.org/I4210148268","display_name":"University of Utah Health Care","ror":"https://ror.org/047s7ex42","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210148268"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jessica A. Walsh","raw_affiliation_strings":["Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, USA","institution_ids":["https://openalex.org/I223532165","https://openalex.org/I4210148268"]}]}],"institutions":[],"countries_distinct_count":6,"institutions_distinct_count":15,"corresponding_author_ids":["https://openalex.org/A5023940584"],"corresponding_institution_ids":["https://openalex.org/I2801941904","https://openalex.org/I2802567020"],"apc_list":{"value":2650,"currency":"USD","value_usd":2650},"apc_paid":{"value":2650,"currency":"USD","value_usd":2650},"fwci":0.6441,"has_fulltext":true,"cited_by_count":2,"citation_normalized_percentile":{"value":0.70894466,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":90,"max":96},"biblio":{"volume":"16","issue":null,"first_page":"1759720X241288071","last_page":"1759720X241288071"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11092","display_name":"Spondyloarthritis Studies and Treatments","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11092","display_name":"Spondyloarthritis Studies and Treatments","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10200","display_name":"Rheumatoid Arthritis Research and Therapies","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/bimekizumab","display_name":"bimekizumab","score":0.949999988079071},{"id":"https://openalex.org/keywords/psoriatic-arthritis","display_name":"psoriatic arthritis","score":1.0},{"id":"https://openalex.org/keywords/patient-reported-outcomes","display_name":"patient-reported outcomes","score":0.8899999856948853},{"id":"https://openalex.org/keywords/tnf-alpha-inhibitors","display_name":"TNF-alpha inhibitors","score":0.5410000085830688},{"id":"https://openalex.org/keywords/acr-response-criteria","display_name":"ACR response criteria","score":0.6930000185966492},{"id":"https://openalex.org/keywords/minimal-disease-activity","display_name":"minimal disease activity","score":0.6909999847412109},{"id":"https://openalex.org/keywords/health-related-quality-of-life","display_name":"health-related quality of life","score":0.7979999780654907},{"id":"https://openalex.org/keywords/pain","display_name":"pain","score":0.9129999876022339},{"id":"https://openalex.org/keywords/fatigue","display_name":"fatigue","score":0.9710000157356262},{"id":"https://openalex.org/keywords/physical-functioning","display_name":"physical function","score":0.9850000143051147},{"id":"https://openalex.org/keywords/il-17-inhibition","display_name":"IL-17 inhibition","score":0.625},{"id":"https://openalex.org/keywords/biological-therapy","display_name":"biologic therapy","score":0.45399999618530273},{"id":"https://openalex.org/keywords/psoriasis-area-and-severity-index","display_name":"Psoriasis Area and Severity Index","score":0.7689999938011169},{"id":"https://openalex.org/keywords/disease-activity","display_name":"disease activity","score":0.3479999899864197}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9396423697471619},{"id":"https://openalex.org/C2776260265","wikidata":"https://www.wikidata.org/wiki/Q511097","display_name":"Psoriatic arthritis","level":3,"score":0.8817237615585327},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5943309664726257},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.5588393807411194},{"id":"https://openalex.org/C2777077863","wikidata":"https://www.wikidata.org/wiki/Q170990","display_name":"Arthritis","level":2,"score":0.49141013622283936},{"id":"https://openalex.org/C142853389","wikidata":"https://www.wikidata.org/wiki/Q744778","display_name":"Association (psychology)","level":2,"score":0.4752231240272522},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4097638726234436},{"id":"https://openalex.org/C1862650","wikidata":"https://www.wikidata.org/wiki/Q186005","display_name":"Physical therapy","level":1,"score":0.35019630193710327},{"id":"https://openalex.org/C138885662","wikidata":"https://www.wikidata.org/wiki/Q5891","display_name":"Philosophy","level":0,"score":0.0},{"id":"https://openalex.org/C111472728","wikidata":"https://www.wikidata.org/wiki/Q9471","display_name":"Epistemology","level":1,"score":0.0}],"mesh":[],"locations_count":4,"locations":[{"id":"doi:10.1177/1759720x241288071","doi":"https://doi.org/10.1177/1759720x241288071","is_oa":true,"landing_page_url":"https://doi.org/10.1177/1759720x241288071","pdf_url":null,"source":{"id":"https://openalex.org/S138391592","display_name":"Therapeutic Advances in Musculoskeletal Disease","issn_l":"1759-720X","issn":["1759-720X","1759-7218"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","norway-1","oarl","poland-140","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Therapeutic Advances in Musculoskeletal Disease","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:11555751","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/11555751","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11555751/pdf/10.1177_1759720X241288071.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Ther Adv Musculoskelet Dis","raw_type":"Text"},{"id":"pmid:39534481","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/39534481","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Therapeutic advances in musculoskeletal disease","raw_type":"Journal Article"},{"id":"pmh:oai:doaj.org/article:8808a439663e4951885d62779c62795b","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/8808a439663e4951885d62779c62795b","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Therapeutic Advances in Musculoskeletal Disease, Vol 16 (2024)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1177/1759720x241288071","doi":"https://doi.org/10.1177/1759720x241288071","is_oa":true,"landing_page_url":"https://doi.org/10.1177/1759720x241288071","pdf_url":null,"source":{"id":"https://openalex.org/S138391592","display_name":"Therapeutic Advances in Musculoskeletal Disease","issn_l":"1759-720X","issn":["1759-720X","1759-7218"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","norway-1","oarl","poland-140","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Therapeutic Advances in Musculoskeletal Disease","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307105","display_name":"Amgen","ror":"https://ror.org/03g03ge92"},{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"},{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"},{"id":"https://openalex.org/F4320307781","display_name":"Sanofi","ror":"https://ror.org/027vj4x92"},{"id":"https://openalex.org/F4320308573","display_name":"Gilead Sciences","ror":"https://ror.org/056546b03"},{"id":"https://openalex.org/F4320308604","display_name":"Biogen","ror":"https://ror.org/02jqkb192"},{"id":"https://openalex.org/F4320309086","display_name":"Celgene","ror":"https://ror.org/0527yg379"},{"id":"https://openalex.org/F4320328070","display_name":"Sun Pharma","ror":"https://ror.org/04vnqkx80"},{"id":"https://openalex.org/F4320332195","display_name":"Samsung","ror":"https://ror.org/04w3jy968"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":31,"referenced_works":["https://openalex.org/W1994621214","https://openalex.org/W2022466169","https://openalex.org/W2033299724","https://openalex.org/W2038157111","https://openalex.org/W2083180635","https://openalex.org/W2102347458","https://openalex.org/W2132309748","https://openalex.org/W2161344815","https://openalex.org/W2400418900","https://openalex.org/W2585071281","https://openalex.org/W2806678383","https://openalex.org/W2883410653","https://openalex.org/W2901986848","https://openalex.org/W2924267368","https://openalex.org/W3004527951","https://openalex.org/W3028154460","https://openalex.org/W3044340626","https://openalex.org/W3081361112","https://openalex.org/W3096826783","https://openalex.org/W3102199713","https://openalex.org/W3139191975","https://openalex.org/W3159598855","https://openalex.org/W4220925623","https://openalex.org/W4283589104","https://openalex.org/W4285084582","https://openalex.org/W4311026127","https://openalex.org/W4311115611","https://openalex.org/W4386615476","https://openalex.org/W4392787310","https://openalex.org/W4392926454","https://openalex.org/W4401217261"],"related_works":["https://openalex.org/W7161641257","https://openalex.org/W6979731050","https://openalex.org/W4311339326","https://openalex.org/W4379800307","https://openalex.org/W4402748743","https://openalex.org/W4395113061","https://openalex.org/W4409867968","https://openalex.org/W4407065557","https://openalex.org/W4409899113","https://openalex.org/W4396947387"],"abstract_inverted_index":{"Background:":[0],"Psoriatic":[1,142],"arthritis":[2],"(PsA)":[3],"is":[4],"a":[5],"chronic":[6],"inflammatory":[7],"disease":[8,77,162,192,258,273],"that":[9],"causes":[10],"pain":[11,225],"and":[12,17,31,39,54,80,104,117,144,150,156,165,173,180,214,228,246,261,298],"fatigue,":[13,170],"reduces":[14],"physical":[15,171],"function,":[16,172],"negatively":[18],"impacts":[19],"health-related":[20],"quality":[21],"of":[22,96,130,148,168,188,212,216,256,268,272,289],"life":[23],"(HRQoL).":[24],"In":[25],"the":[26,70,145,229,254],"phase":[27,98],"III":[28,99],"BE":[29,32,102,105],"OPTIMAL":[30,103],"COMPLETE":[33,106],"studies,":[34],"bimekizumab":[35,109,286],"demonstrated":[36],"clinical":[37,76,161,191,257],"efficacy":[38],"meaningful":[40],"improvements":[41,81,201,223,232,280],"in":[42,47,82,85,115,153,202,224,281],"patient-reported":[43],"outcome":[44,147],"(PRO)":[45],"measures":[46,84,167,263],"biologic":[48],"disease-modifying":[49],"antirheumatic":[50],"drug":[51],"(bDMARD)-na\u00efve":[52],"patients,":[53],"those":[55],"who":[56],"had":[57],"prior":[58,290],"inadequate":[59],"response/intolerance":[60],"to":[61],"tumor":[62],"necrosis":[63],"factor":[64],"inhibitors":[65],"(TNFi-IR).":[66],"Objectives:":[67],"To":[68],"examine":[69],"association":[71],"between":[72,160],"achieving":[73,219],"increasingly":[74,189,269],"stringent":[75,190,270],"control":[78,124,163,193,259,274],"criteria":[79,164,194,260],"PRO":[83,166,204,262],"patients":[86,119,218,284],"with":[87,120,198,277],"active":[88,121],"PsA":[89],"receiving":[90,285],"bimekizumab.":[91],"Design:":[92],"Post":[93],"hoc":[94],"analysis":[95],"two":[97],"studies.":[100],"Methods:":[101],"assessed":[107,126,176,249],"subcutaneous":[108],"160":[110],"mg":[111],"every":[112],"4":[113],"weeks":[114],"bDMARD-na\u00efve":[116,213],"TNFi-IR":[118,217],"PsA.":[122],"Disease":[123,136,138],"was":[125,195,239,275],"using":[127],"American":[128],"College":[129],"Rheumatology":[131],"(ACR)":[132],"response":[133],"criteria,":[134],"Minimal":[135],"Activity,":[137],"Activity":[139],"Index":[140],"for":[141,283],"Arthritis,":[143],"composite":[146],"ACR50":[149],"100%":[151],"improvement":[152],"Psoriasis":[154],"Area":[155],"Severity":[157],"Index.":[158],"Associations":[159],"pain,":[169],"HRQoL":[174],"were":[175],"at":[177,250],"week":[178,181,209,244,251],"16":[179,245],"52/40":[182,252],"(BE":[183],"OPTIMAL/BE":[184],"COMPLETE).":[185],"Results:":[186],"Achievement":[187],"generally":[196],"associated":[197,276],"sequentially":[199],"greater":[200,279],"all":[203],"measures,":[205],"including":[206],"pain.":[207],"At":[208],"52/40,":[210],"94.7%":[211],"97.6%":[215],"ACR70":[220],"reported":[221],"\u2a7e50%":[222],"from":[226],"baseline,":[227],"greatest":[230],"numerical":[231],"(-48.5":[233],"bDMARD-na\u00efve;":[234],"-54.7":[235],"TNFi-IR).":[236],"This":[237],"pattern":[238],"evident":[240],"as":[241,243],"early":[242],"sustained":[247],"when":[248],"across":[253],"majority":[255],"reported.":[264],"Conclusion:":[265],"The":[266],"achievement":[267],"thresholds":[271],"corresponding":[278],"PROs,":[282],"treatment,":[287],"irrespective":[288],"TNFi":[291],"use.":[292],"Trial":[293],"registration":[294],"ClinicalTrialsgov:":[295],"NCT03895203,":[296],"NCT03896581,":[297],"NCT04009499.":[299]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1}],"updated_date":"2026-10-29T09:56:32.521200","created_date":"2024-11-11T00:00:00"}